JAMA Oncology Highlights Plinabulin's Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
29 sept. 2020 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology...
New Data Highlights BeyondSpring’s Plinabulin as a Highly Effective Agent for Preventing Chemotherapy-Induced Neutropenia, with Potential to Reduce Clinical Resources for COVID-19
24 sept. 2020 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology...
BeyondSpring Appoints Elizabeth Czerepak as Chief Financial Officer
22 sept. 2020 08h30 HE
|
BeyondSpring, Inc.
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Following its recent receipt of two Breakthrough Therapy Designations in both the U.S. and China for Plinabulin in the chemotherapy-induced neutropenia...
BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
11 sept. 2020 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology...
BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication
08 sept. 2020 07h00 HE
|
BeyondSpring, Inc.
- FDA Breakthrough Designation for CIN Indication: Plinabulin for Concurrent Administration with Myelosuppressive Chemotherapeutic Regimens in Patients with Non-Myeloid Malignancies for the Prevention...
BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates
03 sept. 2020 07h00 HE
|
BeyondSpring, Inc.
- Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulin’s Superiority in Combination with Neulasta for CIN Prevention vs. Neulasta...
BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020
27 août 2020 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors
18 août 2020 08h00 HE
|
BeyondSpring, Inc.
NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative...
BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.
11 août 2020 08h00 HE
|
BeyondSpring, Inc.
- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients - - First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with...
New Stem Cell-Based Application for BeyondSpring’s Plinabulin Presented at ISSCR Annual Meeting
30 juin 2020 07h00 HE
|
BeyondSpring, Inc.
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative...